AAA
CBIO

Affinity Asset Advisors’s Crescent Biopharma CBIO Stock Holding History

Affinity Asset Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,423
Closed -$427K – 111
2024
Q1 		$427K Buy
+1,423
New +$425K 0.05% 91
2023
Q2 		– Sell
-3,000
Closed -$378K – 80
2023
Q1 		$378K Buy
+3,000
New +$675K 0.12% 68

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Affinity Asset Advisors's CBIO Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Crescent Biopharma (CBIO) in Q4 2025, closing a stake of 17,998 shares — an estimated $214K sold.

Affinity Asset Advisors first reported a position in CBIO in Q2 2025 and held it in 2 quarters. The position peaked at $4.52M in Q2 2025. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Crescent Biopharma position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 17,998 Crescent Biopharma shares in Q4 2025, an estimated $214K.
  • Affinity Asset Advisors first reported a position in Crescent Biopharma in Q2 2025 and held it in 2 quarters.
  • Affinity Asset Advisors's Crescent Biopharma position peaked at $4.52M in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.